During therapy for CML-CP, there are specific recommendations regarding achieving target molecular responses at different time points (3, 6, 12 months) by measuring BCR::ABL transcript levels using real-time reverse transcriptase polymerase chain reaction (RT-PCR), as outlined in international standards (IS) (35, 36). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.